Cargando…
Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast
AIMS: Here we explore the presence of mediator complex subunit 12 (MED12) exon 2 and telomerase reverse transcriptase (TERT) promoter hotspot mutations in complex fibroadenomas (CFAs) of the breast. METHODS: The stromal components from 18 CFAs were subjected to Sanger sequencing of MED12 exon 2 and...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260148/ https://www.ncbi.nlm.nih.gov/pubmed/33376197 http://dx.doi.org/10.1136/jclinpath-2020-207062 |
_version_ | 1783718770208931840 |
---|---|
author | da Silva, Edaise M Beca, Francisco Sebastiao, Ana Paula Martins Murray, Melissa P Silveira, Catarina Da Cruz Paula, Arnaud Pareja, Fresia Wen, Hannah Y D'Alfonso, Timothy M Edelweiss, Marcia Weigelt, Britta Brogi, Edi Reis-Filho, Jorge S Zhang, Hong |
author_facet | da Silva, Edaise M Beca, Francisco Sebastiao, Ana Paula Martins Murray, Melissa P Silveira, Catarina Da Cruz Paula, Arnaud Pareja, Fresia Wen, Hannah Y D'Alfonso, Timothy M Edelweiss, Marcia Weigelt, Britta Brogi, Edi Reis-Filho, Jorge S Zhang, Hong |
author_sort | da Silva, Edaise M |
collection | PubMed |
description | AIMS: Here we explore the presence of mediator complex subunit 12 (MED12) exon 2 and telomerase reverse transcriptase (TERT) promoter hotspot mutations in complex fibroadenomas (CFAs) of the breast. METHODS: The stromal components from 18 CFAs were subjected to Sanger sequencing of MED12 exon 2 and the TERT promoter hotspot loci. The epithelial and stromal components of two MED12 mutated CFAs were subjected to laser capture microdissection, and Sanger sequencing of MED12 exon 2, TERT promoter and PIK3CA exons 9 and 20, separately. RESULTS: MED12 exon 2 mutations were identified in the stroma of 17% of CFAs. The analyses of epithelial and stromal components, microdissected separately, revealed that MED12 mutations were restricted to the stroma. No TERT promoter or PIK3CA mutations in exons 9 and 20 were detected in analysed CFAs. CONCLUSIONS: Like conventional fibroadenomas, MED12 exon 2 mutations appear to be restricted to the stromal component of CFAs, supporting the notion that CFAs are stromal neoplasms. |
format | Online Article Text |
id | pubmed-8260148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-82601482022-02-07 Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast da Silva, Edaise M Beca, Francisco Sebastiao, Ana Paula Martins Murray, Melissa P Silveira, Catarina Da Cruz Paula, Arnaud Pareja, Fresia Wen, Hannah Y D'Alfonso, Timothy M Edelweiss, Marcia Weigelt, Britta Brogi, Edi Reis-Filho, Jorge S Zhang, Hong J Clin Pathol Short Report AIMS: Here we explore the presence of mediator complex subunit 12 (MED12) exon 2 and telomerase reverse transcriptase (TERT) promoter hotspot mutations in complex fibroadenomas (CFAs) of the breast. METHODS: The stromal components from 18 CFAs were subjected to Sanger sequencing of MED12 exon 2 and the TERT promoter hotspot loci. The epithelial and stromal components of two MED12 mutated CFAs were subjected to laser capture microdissection, and Sanger sequencing of MED12 exon 2, TERT promoter and PIK3CA exons 9 and 20, separately. RESULTS: MED12 exon 2 mutations were identified in the stroma of 17% of CFAs. The analyses of epithelial and stromal components, microdissected separately, revealed that MED12 mutations were restricted to the stroma. No TERT promoter or PIK3CA mutations in exons 9 and 20 were detected in analysed CFAs. CONCLUSIONS: Like conventional fibroadenomas, MED12 exon 2 mutations appear to be restricted to the stromal component of CFAs, supporting the notion that CFAs are stromal neoplasms. BMJ Publishing Group 2022-02 2020-12-29 /pmc/articles/PMC8260148/ /pubmed/33376197 http://dx.doi.org/10.1136/jclinpath-2020-207062 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Short Report da Silva, Edaise M Beca, Francisco Sebastiao, Ana Paula Martins Murray, Melissa P Silveira, Catarina Da Cruz Paula, Arnaud Pareja, Fresia Wen, Hannah Y D'Alfonso, Timothy M Edelweiss, Marcia Weigelt, Britta Brogi, Edi Reis-Filho, Jorge S Zhang, Hong Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast |
title | Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast |
title_full | Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast |
title_fullStr | Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast |
title_full_unstemmed | Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast |
title_short | Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast |
title_sort | stromal med12 exon 2 mutations in complex fibroadenomas of the breast |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260148/ https://www.ncbi.nlm.nih.gov/pubmed/33376197 http://dx.doi.org/10.1136/jclinpath-2020-207062 |
work_keys_str_mv | AT dasilvaedaisem stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT becafrancisco stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT sebastiaoanapaulamartins stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT murraymelissap stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT silveiracatarina stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT dacruzpaulaarnaud stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT parejafresia stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT wenhannahy stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT dalfonsotimothym stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT edelweissmarcia stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT weigeltbritta stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT brogiedi stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT reisfilhojorges stromalmed12exon2mutationsincomplexfibroadenomasofthebreast AT zhanghong stromalmed12exon2mutationsincomplexfibroadenomasofthebreast |